Literature DB >> 19193987

Acquired pericentric inversion of chromosome 9 in acute myeloid leukemia.

A M Udayakumar1, A V Pathare, D Dennison, J A Raeburn.   

Abstract

Pericentric inversion of chromosome 9 involving the qh region is relatively common as a constitutional genetic aberration without any apparent phenotypic consequences. However, it has not been established as an acquired abnormality in cancer. Among the three patients reported so far in the literature with acquired inv(9), only one had acute myeloid leukemia (AML). Here we describe an unique case where both chromosomes 9 presented with an acquired pericentric inversion with breakpoints at 9p13 and 9q12 respectively, in a AML patient with aberrant CD7 and CD9 positivity. Additionally, one der(9) also showed short arm deletion at 9p21 to the centromeric region and including the p16 gene. The constitutional karyotype was normal. This is probably the first report describing an acquired inv(9) involving both chromosomes 9 in AML. The possible significance of this inversion is discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193987     DOI: 10.1007/BF03195656

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  14 in total

1.  Acquired pericentric inversion of chromosome 9 in essential thrombocythemia.

Authors:  T S Wan; S K Ma; L C Chan
Journal:  Hum Genet       Date:  2000-06       Impact factor: 4.132

2.  Homologous sequences at human chromosome 9 bands p12 and q13-21.1 are involved in different patterns of pericentric rearrangements.

Authors:  Heike Starke; Jörg Seidel; Wolfram Henn; Sylvia Reichardt; Marianne Volleth; Markus Stumm; Christine Behrend; Klaus R Sandig; Christine Kelbova; Gabriele Senger; Beate Albrecht; Ingo Hansmann; Anita Heller; Uwe Claussen; Thomas Liehr
Journal:  Eur J Hum Genet       Date:  2002-12       Impact factor: 4.246

Review 3.  Issues in the etiology of recurrent spontaneous abortion.

Authors:  S Daya
Journal:  Curr Opin Obstet Gynecol       Date:  1994-04       Impact factor: 1.927

4.  A possible subgroup of ALL with 9p-.

Authors:  J Kowalczyk; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1983-08

5.  The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.

Authors:  S Faderl; H M Kantarjian; E Estey; T Manshouri; C Y Chan; A Rahman Elsaied; S M Kornblau; J Cortes; D A Thomas; S Pierce; M J Keating; Z Estrov; M Albitar
Journal:  Cancer       Date:  2000-11-01       Impact factor: 6.860

6.  The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster.

Authors:  R C Aguiar; H Sill; J M Goldman; N C Cross
Journal:  Leukemia       Date:  1997-02       Impact factor: 11.528

7.  Acquired inv(9): what is its significance?

Authors:  Jaime L Betz; Ahmed S Behairy; Pedro Rabionet; Budi Tirtorahardjo; Mathew W Moore; Philip D Cotter
Journal:  Cancer Genet Cytogenet       Date:  2005-07-01

8.  Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9.

Authors:  R R Chilcote; E Brown; J D Rowley
Journal:  N Engl J Med       Date:  1985-08-01       Impact factor: 91.245

9.  Pericentric inversion of chromosome 9 in prenatal diagnosis and infertility.

Authors:  S Uehara; Y Akai; Y Takeyama; T Takabayashi; K Okamura; A Yajima
Journal:  Tohoku J Exp Med       Date:  1992-04       Impact factor: 1.848

Review 10.  Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.

Authors:  H G Drexler
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

View more
  1 in total

1.  Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.

Authors:  Matjaz Sever; Hagop Kantarjian; Sherry Pierce; Nitin Jain; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.